Abstracts tagged "Biologicals"

Abstract Number: 1387 • ACR Convergence 2024
Olokizumab Effect on Chronic Pain in Rheumatoid Arthritis: Results of the Observational Study
Andrey Karateev¹, Sofia Kuzkina², Galym Togizbayev³, Elena Polishuk¹, Ekaterina Filatova¹, Vera Amirdzhanova¹, Victoria Khlaboshchina¹, Natalia Lapkina⁴, Andrey Baranov⁴ and Alexander Lila⁵, ¹V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia, ²R-Pharm, Moscow, Russia, ³Kazakh National Medical University named after Asfendiyarov S, Almaty, Kazakhstan, ⁴Yaroslavl State Medical University, Yaroslavl, Russia, ⁵Russian Medical Academy of Continuous Professional Education of the Ministry of Healthcare of the Russian Federation, Moscow, Russia
Background/Purpose: To evaluate efficacy and safety of olokizumab (interleukin-6 inhibitor) in RA patients with special attention to chronic pain and a signs of central sensitization.Methods:…
Abstract Number: 1495 • ACR Convergence 2024
Real-World Reduction in Disease Flares and Oral Corticosteroid Use with Anifrolumab Therapy in Systemic Lupus Erythematosus: A Claims-Based Study
Mawuena Binka¹, Rana Muhammad Qasim Khan², Joseph Tkacz³, Donna McMorrow³, Laurence Gozalo³ and Gail Kerr⁴, ¹BioPharmaceuticals Medical, AstraZeneca, Wilmington, DE, ²BioPharmaceuticals Medical, AstraZeneca, Wilmington, ³Inovalon, Bowie, MD, ⁴Veterans Affairs Medical Center, Georgetown and Howard University Hospitals, Washington, DC
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex, chronic autoimmune disease characterized by frequent episodes of disease activity (flares) of varying severity.1 SLE flares are…
Abstract Number: 1864 • ACR Convergence 2024
S-4321, a Novel Dual-cell Bidirectional PD-1:FcγRIIb Selective Agonist Antibody for the Treatment of Autoimmune Disease
Julia Manasson¹, Marisella Panduro², Michael Cianci², Minasri Borah², Stephanie Grebinoski², Joshua Vitlip², Stephen Lutz², Ishan Sharma², Elliott Wittenberg², Allison Colthart², Samuel Perry², Maria Cecilia Ramello², Chelsea R. Parker Harp², Jyothsna Visweswaraiah², Ryan Peckner², Alex Pellerin², Heather Vital³, John Sundy⁴, Nathan Higginson-Scott², Kevin L. Otipoby² and Daniela Cipolletta², ¹Seismic Therapeutic, New York, NY, ²Seismic Therapeutic, Watertown, MA, ³Seismic Therapeutic, Lexington, MA, ⁴Seismic Therapeutic, Chapel Hill, NC
Background/Purpose: The dysregulation of immune checkpoint receptors on T cells and antigen presenting cells (APCs) drives autoimmunity while receptor agonism is expected to restore immune…
Abstract Number: 2144 • ACR Convergence 2024
Impact of Immunogenicity on Clinical Outcomes in Postmenopausal Women with Osteoporosis: Results from a Randomized Controlled Phase 3 Study to Compare CT-P41 (Proposed Denosumab Biosimilar) and Reference Denosumab
Jean-Yves Reginster¹, Stuart L. Silverman², Edward Czerwinski³, Przemyslaw Borowy⁴, Tomasz Budlewski⁵, Joanna Kwiatek⁶, Svitlana Postol⁷, Airi Põder⁸, Jerzy Supronik⁹, SungHyun Kim¹⁰, JeeHye Suh¹⁰, GoEun Yang¹⁰, NooRi Han¹⁰, NaHyun Kim¹⁰ and SeoHee Bae¹⁰, ¹Biochemistry Dept, College of Science, King Saud University, Riyadh, Kingdom of Saudi Arabia, CLARENS, Switzerland, ²OMC clinical research center and Cedars Sinai Medical Center, Beverly Hills, CA, ³Krakowskie Centrum Medyczne, Kraków, Poland, ⁴Krakowskie Centrum Medyczne, Krakow, Poland, ⁵Department of Rheumatology, Medical University of Lodz, Lodz, Poland, ⁶Centrum Medyczne Poznan - PRATIA, Skorzewo, Poland, ⁷Medical Center of Medbud - Clinic LLC, Kyiv, Ukraine, ⁸Clinical Research Centre Ltd, Tartu, Estonia, ⁹Osteo-Medic s.c., Białystok, Poland, ¹⁰Celltrion, Inc., Incheon, Republic of Korea

Background/Purpose: CT-P41 has been developed as a proposed biosimilar of the reference denosumab (DEN), a fully human monoclonal antibody that binds the cytokine receptor activator…
Abstract Number: 2364 • ACR Convergence 2024
Reporting Mental Health and Associated Disorders from Trials of Bimekizumab in Patients with Active Axial Spondyloarthritis and Psoriatic Arthritis
Marina Magrey¹, Denis Poddubnyy², Mark Lebwohl³, Rajan Bajracharya⁴, Dirk de Cuyper⁵, Alexander Marten⁶, Luke Peterson⁷, Jeffrey L. Stark⁸ and Joseph F. Merola⁹, ¹Case Western Reserve University School of Medicine/University Hospitals, Richfield, OH, ²Charite-Universitatsmedizin Berlin, Berlin, Germany, ³Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, ⁴UCB Pharma, Slough, United Kingdom, ⁵UCB Pharma, Brussels, Belgium, ⁶UCB Pharma, Monheim am Rhein, Germany, ⁷UCB Pharma, Morrisville, NC, ⁸UCB Pharma, Smyrna, GA, ⁹UT Southwestern Medical Center, Dallas, TX
Background/Purpose: Anxiety and depression are highly prevalent in patients (pts) with axial spondyloarthritis (axSpA)/PsA.1,2 We report mental health data in pts with axSpA/PsA from trials…
Abstract Number: 2609 • ACR Convergence 2024
Drivers of Infliximab Biosimilar Uptake: A Comparative Analysis of New Biosimilar Initiations versus Switching in a National Rheumatology Registry
Eric Roberts¹, Nick Bansback², Chien-Wen Tseng³, Steve Shiboski⁴, Jing Li⁵, Gabriela Schmajuk⁶ and Jinoos Yazdany⁷, ¹University of California, San Francisco, SF, CA, ²University of British Columbia, Vancouver, BC, Canada, ³University of Hawai'i John A. Burns School of Medicine, Honolulu, ⁴University of California, San Francisco, San Francisco, ⁵University of California, San Francisco, San Francisco, CA, ⁶UCSF / SFVA, San Francisco, CA, ⁷UCSF, San Francisco, CA
Background/Purpose: Biosimilars hold promise for reducing pharmaceutical expenditures, however uptake has lagged. We analyzed the variability in new biosimilar starts and switching from bio-originator infliximab…
Abstract Number: 0243 • ACR Convergence 2024
Humoral Response to SARS-CoV-2 Vaccination and Breakthrough COVID-19 Disease in Patients with Immune-mediated Inflammatory Diseases Receiving Biological Treatment
Eve-Kai Raussi, Maigi Eisen, Küllike Palk and Marge Kütt, North Estonia Medical Centre Foundation, Tallinn, Estonia
Background/Purpose: Immune response in patients with immune-mediated inflammatory diseases (IMID) is compromised. As SARS-CoV-2 vaccine trials excluded patients on immunosuppressive therapy, data about vaccination efficacy…
Abstract Number: 0501 • ACR Convergence 2024
How Fast Do JAK-inhibitors, TNF-inhibitors, Abatacept and IL-6 Inhibitors Act in Rheumatoid Arthritis? An International Collaboration of Registers of Rheumatoid Arthritis Patients (the “JAK-pot” Study)
Delphine Sophie Courvoisier¹, Yacine Mrad¹, Denis Mongin¹, Romain Aymon², Roberto Caporali³, Denis Choquette⁴, Catalin Codreanu⁵, Louis Coupal⁴, Doreen Huschek⁶, Kimme Hyrich⁷, Florenzo Iannone⁸, Tore K. Kvien⁹, Monika Mustak¹⁰, Dan Nordstrom¹¹, Nina Trokovic¹², Lucia Otero-Varela¹³, Karel Pavelka¹⁴, Manuel Enrique Pombo Suarez¹⁵, Sella A. Provan¹⁶, Ana Maria Rodrigues¹⁷, Ziga Rotar¹⁸, Prodromos Sidiropoulos¹⁹, Anja Strangfeld²⁰, Jakub Závada¹⁴, Sizheng Zhao²¹, Axel Finckh¹ and Kim Lauper¹, ¹Division of Rheumatology, Geneva University Hospitals, Geneva, Switzerland, ²Division of Rheumatology, Geneva University Hospitals, Collonges-sous-Salève, France, ³Department of Clinical Sciences and Community Health, University of Milan, and Department of Rheumatology and Medical Sciences, ASST Gaetano Pini-CTO, Milan, Italy, ⁴Rhumadata™, Montreal, QC, Canada, ⁵University of Medicine and Pharmacy, Bucharest, Romania, ⁶German Rheumatism Research Center (DRFZ) Berlin, Berlin, Germany, ⁷Centre for Musculoskeletal Research, The University of Manchester, Manchester, United Kingdom, ⁸Rheumatology Unit- University of Bari "Aldo Moro", IT, Bari, Italy, ⁹Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway and University of Oslo (UiO), Institute of Clinical Medicine, Oslo, Norway, Oslo, Norway, ¹⁰Department of Internal Medicine II, Kaiser Franz Josef Hospital, Vienna, Austria, ¹¹Helsinki University Hospital, Helsinki, Finland, ¹²Department of Medicine and Rheumatology ROB-FIN, Helsinki University Hospital, Helsinki, Finland, ¹³Spanish Society of Rheumatology, Madrid, Spain, ¹⁴Institute of Rheumatology and Charles University, Praha, Czech Republic, ¹⁵Rheumatology Department, Complejo Hospitalario Universitario de Santiago de Compostela, Santiago de Compostela, Spain, ¹⁶Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, Oslo, Norway, ¹⁷Nova Medical School and Hospital dos Lusíadas, Lisbon, Portugal, ¹⁸University Medical Centre Ljubljana and University of Ljubljana, Ljubljana, Slovenia, ¹⁹University of Crete, Laboratory of Rheumatology, Autoimmunity and Inflammation. University Hospital, Rheumatology, Clinical Immunology. Institute of Molecular Biology and Biotechnology, Foundation for Research and Technology, Heraklion, Greece, HERAKLIO, Greece, ²⁰German Rheumatism Research Center (DRFZ) Berlin and Charité University Medicine, Berlin, Germany, ²¹Centre for Musculoskeletal Research, The University of Manchester, Liverpool, United Kingdom
Background/Purpose: JAK-inhibitors (JAKi) have demonstrated a rapid onset of action; however, it is unclear how they compare to other targeted therapies in rheumatoid arthritis (RA).…
Abstract Number: 0572 • ACR Convergence 2024
Synergistic Impact of the Non-radiographic Axial Spondyloarthritis Subtype and Female Sex on First-Line Biologic Discontinuation : A Study of Interaction Effects
Patricia Remalante-Rayco¹, Emmanuel Baja², Zeynep Baskurt³, Tina Chim⁴, Robert Inman⁵, Leonila Dans⁶ and Nigil Haroon⁷, ¹Schroeder Arthritis Institute, Toronto Western Hospital, University Health Network, Toronto, ON, Canada, ²Institute of Clinical Epidemiology, National Institutes of Health, University of the Philippines Manila, Manila, Philippines, ³Department of Biostatistics, University Health Network, Toronto, Canada, ⁴Schroeder Arthritis Institute, Toronto Western Hospital, University Health Network, Toronto, Canada, ⁵University Health Network, Toronto, ON, Canada, ⁶Department of Clinical Epidemiology, College of Medicine, University of the Philippines Manila, Manila, Philippines, ⁷Department of Medicine/Rheumatology, University Health Network, Schroeder Arthritis Institute, University of Toronto, Toronto, ON, Canada
Background/Purpose: Recent evidence suggests lower response rates to tumor necrosis factor inhibitors (TNFi) among women with non-radiographic axial spondyloarthritis (nr-axSpA). However, there is a paucity…
Abstract Number: 0748 • ACR Convergence 2024
Effectiveness of Interleukin-6 Receptor Inhibitors versus Conventional Synthetic Immunomodulatory Therapy for Treatment of Frail Patients with Polymyalgia Rheumatica
Sebastian E. Sattui¹, Christian Dejaco², Kerri Ford³, Stefano Fiore⁴, Sebastian Unizony⁵, Fenglong Xie⁶ and Jeffrey Curtis⁷, ¹University of Pittsburgh, Pittsburgh, PA, ²Rheumatology, Hospital of Bruneck (ASAA-SABES), Teaching Hospital of the Paracelsius Medical University, Brunico, Italy, ³Sanofi, Cambridge, MA, ⁴Sanofi, Bridgewater, NJ, ⁵Massachusetts General Hospital, Winchester, MA, ⁶University of Alabama at Birmingham, Birmingham, AL, ⁷The University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Treatment of polymyalgia rheumatica (PMR) is hindered by lack of glucocorticoid (GC)-sparing therapies with proven efficacy. A retrospective study showed a higher proportion of…
Abstract Number: 1038 • ACR Convergence 2024
IMPACT (Impact of eMbedded Pharmacists in an Academic Center sTudy)
Sukul Mittal¹, Prajwal Dara¹, Omkar Dhamankar², Noelle Cordova¹, Saba Mohiuddin¹, Aemen Zamir¹, Joshua Blackwell¹, Paula Mofor¹, Christian Alvarez¹, Anjali Kalra¹, Song Zhang¹, Nilofar Syed¹ and Puneet Bajaj³, ¹University of Texas Southwestern Medical Center, Dallas, TX, ²University of Texas Southwestern Medical Center, Dallas, UT, ³UT Southwestern Medical Center, Dallas, TX
Background/Purpose: Clinical pharmacists (CPs) embedded within outpatient clinics have revolutionized the impact of provided services and have the potential to improve various aspects of clinical…
Abstract Number: 1389 • ACR Convergence 2024
Cohort Study on Drug Survival and Tolerability of Adalimumab Biosimilar Transitioning: Pharmaceutical Properties Do Matter
Amy Peeters¹, Maike Wientjes², Wieland Müskens¹, David Ten Cate³, Bart van den Bemt⁴, Noortje van Herwaarden¹ and Alfons den Broeder², ¹Sint maartenskliniek, Nijmegen, Netherlands, ²Sint Maartenskliniek, Ubbergen, Netherlands, ³Sint Maartenskliniek, Rotterdam, Netherlands, ⁴Sint Maartenskliniek / Radboudumc, Ubbergen, Netherlands
Background/Purpose: Since the compound patent on the bio-originator of adalimumab expired, several adalimumab biosimilars (BS) have been introduced. Extensive research shows equivalence in effectiveness and…
Abstract Number: 1527 • ACR Convergence 2024
Comparative Harms in Patients with Systemic Lupus Erythematosus Treated with Anifrolumab or Belimumab: A Multicenter Cohort Study Using the TriNetX Research Network
Hsin-Hua Chen, Division of Allergy, Immunology and Rheumatology, Taichung Veterans General Hospital, Taichung, Taiwan (Republic of China)

Background/Purpose: Belimumab and anifrolumab, biologic therapies, have shown to improve systemic lupus erythematosus (SLE) outcomes in clinical trials, but there is a lack of real-world…
Abstract Number: 1903 • ACR Convergence 2024
Impact of Multimorbidity on Targeted Synthetic and Biologic Disease-modifying Antirheumatic Drug (ts/bDMARD) Effectiveness in Patients with Rheumatoid Arthritis: A Two Year Follow-up Study from Mexican Adverse Events Registry BIOADAMEX
Vijaya Rivera Teran¹, David Vega Morales², Iris Jazmín Colunga Pedraza³, Sandra Sicsik Ayala⁴, Angel Alejandro Castillo Ortiz⁵, Miguel Angel Saavedra Salinas⁶, Dafhne Miranda Hernández⁷, Fedra Irazoque Palazuelos⁸, Julio César Casasola Vargas⁹, Omar Eloy Muñoz Monroy¹⁰, Sandra Carrillo Vazquez⁸, javier Merayo Chalico¹¹, Guillermo Guaracha Basañez¹², Estefania Torres Valdez¹³, Luis Valdés Corona¹⁴, Angélica Peña Ayala¹⁵, Sergio Durán Barragán¹⁶, Azucena Ramos Sánchez², Aleni Paz Viscarra¹⁴, Erick Adrián Zamora Tehozol¹⁷, Daniel Xibillé Friedman¹⁸ and Jiram Torres Ruiz¹⁹, ¹Colegio Mexicano de Reumatología, Mexico City, Mexico, ²Instituto Mexicano del Seguro Social, Monterrey, Mexico, ³Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, ⁴Instituto Mexicano del Seguro Social, Torreón, Mexico, ⁵Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado, Merida, Mexico, ⁶División de Investigación en Salud, Hospital de Especialidades Dr. Antonio Fraga Mouret, CMN La Raza, CDMX, Mexico, ⁷Instituto Mexicano del Seguro Social, Mexico City, Mexico, ⁸Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado, Mexico City, Mexico, ⁹Hospital General de México, “Dr.Eduardo Liceaga”, MEXICO CITY, Mexico, ¹⁰Hospital Central Militar, Mexico City, Mexico, ¹¹Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, CDMX, Mexico, ¹²Instituto Nacional de Ciencias Médicas y Nutrición "Salvador Zubirón", Mexico City, Mexico, ¹³Instituto Mexicano del Seguro Social, Querétaro, Mexico, ¹⁴Práctica Privada, Mexico City, Mexico, ¹⁵Instituto Nacional de Rehabilitación "Luis Guillermo Ibarra Ibarra", Ciudad de Mexico, Distrito Federal, Mexico, ¹⁶Clínica de Investigación en Reumatología, Guadalajara, Mexico, ¹⁷Práctica Privada, Merida, Mexico, ¹⁸Práctica Privada, Cuernavaca, Mexico, ¹⁹INCMNSZ, Mexico, Federal District, Mexico
Background/Purpose: To evaluate the impact of multimorbidity on the effectiveness of targeted synthetic and biologic disease-modifying antirheumatic drug (ts/bDMARD), in patients with rheumatoid arthritis in a two-year follow-up.Methods:…
Abstract Number: 2177 • ACR Convergence 2024
CD59 Complement Membrane Regulator Deficiency: 12 Years of Clinical and Molecular Follow-up of 29 Patients
Dror Mevorach, Netanel Karbian, Marian Zeibak and Adi Tabib, Hadassah-University Hospital, Jerusalem, Israel
Background/Purpose: We have described in 2013, homozygous CD59-deficient children that manifest with recurrent peripheral neuropathy resembling Guillain-Barré syndrome (GBS), with hemolytic anemia and recurrent strokes.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].